clinical study retractions – Retraction Watch

Authors defend retracted paper on vitamin D and COVID-19 called ‘deeply bizarre’ by critic

PLOS One has retracted a paper linking vitamin D levels and COVID-19 morbidity three years after a critic flagged the data in the study as “deeply bizarre.” The authors objected to the retraction, with one calling it “outrageous” and pointing to flaws in the published notice.

The article, which appeared in February 2022, claimed people with low levels of vitamin D were at increased risk for severe COVID-19 and were more likely to die of the disease than other patients. It has been cited 65 times, according to Clarivate’s Web of Science.

The paper had a “huge, immediate impact,” said Gideon Meyerowitz-Katz, a senior research fellow from the University of Wollongong in Australia, citing the fact that the paper had been viewed over 1 million times within six weeks of being published. The article joins others, many also flagged by Meyerowitz-Katz, purporting to find links between vitamin D intake and COVID-19 severity that have been retracted or removed.

Study on apple cider vinegar for weight loss retracted after many raise concerns

Easy fixes for complex health problems can be tempting — but they rarely pan out. That seems to be the case for the investigators on one clinical trial who claimed consuming apple cider vinegar caused obese teens and young adults to lose weight.

Their article appeared in March 2024 in BMJ Nutrition, Prevention & Health. The journal is retracting the paper “because the authors’ analyses could not be replicated and multiple errors were identified,” according to the retraction notice.

The retraction, dated September 23, comes more than a year after sleuths pointed out some of these errors and other problems with the analysis.

Exclusive: Publisher investigating DNA contamination paper that authors say CDC vaccine committee will consider

The publisher Taylor & Francis is investigating concerns raised on PubPeer about a paper claiming to find DNA contamination in COVID-19 vaccines beyond regulators’ recommended amounts.

The move comes as the U.S. body tasked with making recommendations for vaccine use is scheduled to consider the safety of COVID-19 shots, and two of the study’s authors say their findings will be discussed.

The paper at issue was published September 6 in the journal Autoimmunity, a Taylor & Francis title. Scientific sleuth Kevin Patrick soon posted concerns on PubPeer, which he forwarded to the ethics department of the publisher.

Papers continue to face retractions for failure to license pricy tool

Two journals have retracted papers this year for unauthorized use of a controversial scale whose creator has been known to license use of the questionnaire for six-figure sums – and to aggressively pursue those payments from researchers he claims have misused the instrument without prior approval.

The Morisky Medication Adherence Scale (MMAS) is named for its creator, Donald Morisky, now a professor emeritus in community health at UCLA. As the name implies, the measure allows researchers to assess patients’ adherence to drug regimens.

Morisky made a business out of licensing the scale and demanding steep fees for researchers who failed to obtain the proper permissions, as we reported in Science in 2017. Researchers who cannot afford the payments Morisky and his business associate demand have been forced to retract their work.

‘Tin Man Syndrome’ case plagiarized from hoax, sleuths say

*A comparison of the images and an overlay, provided by a sleuth.*

On April Fools’ Day 10 years ago, radiologist Matt Skalski took part in a website’s annual challenge to prank the radiology community by posting the case of a man with “ectopia cordis interna,” or “Tin Man Syndrome.” Unlike the fictitious metal character from the Wizard of Oz, Skalski’s satirical patient had a heart — in his abdomen.

Now a group of researchers say they encountered the disease in real life, in a 22-year-old patient they claim has “no significant medical history.”

The researchers based in Iraq published their “rare case report” in Medicine in July.

Microbiome company CEO who linked COVID vaccine to bacterial decline now has four retractions

A gastroenterologist and microbiome researcher who has promoted hydroxychloroquine and ivermectin as COVID treatments has lost a paper after a sleuth reported differences between the article and the registered protocol of the clinical trial it purported to describe.

The retracted article, on detecting SARS-CoV-2 in fecal samples, was published in Gut Pathogens in January 2021. It marks the fourth retraction for study coauthor Sabine Hazan.

Hazan is founder and CEO of ProgenaBiome, a laboratory in Ventura, Calif., advertising clinical trials exploring the role of the gut microbiome in conditions including autism and Alzheimer’s disease, as well as COVID. She is also CEO of Ventura Clinical Trials, which lists dozens of pharmaceutical and biotech companies among its clients.

Slovak science academy ‘strictly condemns’ government official’s paper on mRNA vaccines

Slovakia’s national science academy has issued a strong critique of a paper on mRNA vaccines coauthored by a member of the country’s parliament. The group called the work “insufficiently detailed” and “lacking controls,” with data that “may be misleading” and conclusions “not supported by sufficiently robust data.”

Peter Kotlár, the paper’s second author, is an orthopedist and represents the far-right Slovak National Party. He is also the commissioner for a review of resource management during the COVID-19 pandemic for the government of populist prime minister Robert Fico, himself known for questioning the science around COVID-19.

The paper appeared May 13 in the Journal of Angiology and Vascular Surgery, published by Herald Scholarly Open Access. “The journal in which the study of Peter Kotlár was published, is not evidenced in databases Web Of Science and Scopus,” a spokesperson for the Slovak Academy of Sciences, Monika Tináková, told us. The issues with the paper reflect “the fact that the journal in which it was published is classified as a so-called predatory journal,” the statement, issued last month, reads.

Journal investigating placebo effect study following Retraction Watch inquiry

An Elsevier journal is investigating a paper by a controversial author after a Retraction Watch inquiry about the article. The article concluded that “placebo effects have a significant impact on observed outcomes” in both placebo and treatment groups in clinical trials.

The senior author of the paper is Harald Walach, whose name may be familiar. In one paper, now retracted, Walach and his coauthors claimed COVID-19 vaccines killed two people for every three deaths they prevented. In a different paper, also retracted, Walach and his colleagues claimed children’s masks trap carbon dioxide; they later republished the article in a different journal. He lost two papers and a university affiliation in 2021.

One of his latest papers, “Treatment effects in pharmacological clinical randomized controlled trials are mainly due to placebo,” appeared online December 27 in the Journal of Clinical Epidemiology.

Why has it taken more than a year to correct a COVID-19 paper?

A correction to a clinical trial on a potential treatment for COVID-19 has taken more than a year — and counting — to get published. In the meantime, the article remains marked with an expression of concern that appeared in February 2024.

The Lancet Regional Health–Americas published the study, a randomized clinical trial of the effect of metformin on hospitalization rates among COVID-19 patients, in December 2021. It has been cited 36 times, according to Clarivate’s Web of Science, 12 of those since the publication of the expression of concern.

In December 2023, the authors “identified small errors in the statistical analysis primary outcome,” corresponding author Edward Mills, a health research methods professor at McMaster University, in Hamilton, Ontario, told Retraction Watch. “We immediately re-ran the analysis and submitted as an erratum,” he said.

Cureus paper by dean and medical student retracted for mislabeled ECG

The ECG from the retracted paper, which the journal said was mislabeled.

A paper by a medical student and an associate professor in Florida has been retracted for errors with the central finding of the study, an electrocardiogram whose labeling “does not actually represent any of the characteristics” of the tracing.

The paper, “Silent Myocardial Infarction: A Case Report,” was published in Cureus in August 2023 and has been cited once, according to Clarivate’s Web of Science.

The retraction notice dated January 28 details issues with the tracing:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: